A long-running study from Dana-Farber Cancer Institute, published in Nature Cancer and co-funded by OCRA, has discovered that the antibiotic novobiocin is capable of targeting and killing tumor cells in laboratory cell lines and tumor models with BRCA1 or BRCA2 genetic mutations–and is effective even in tumors that have become resistant to PARP inhibitors. BRCA1 … Continued
New research from The Wistar Institute and Peter MacCallum Cancer Center has uncovered a previously unknown checkpoint mechanism for gene expression, that may open up new avenues for transcription-based targeted cancer therapies in the future. This exciting study, published in the cancer journal Cell, was made possible in part by an OCRA research grant to … Continued
OCRA-funded researcher Anil K. Sood, M.D., lead and senior author, and Sanghoon Lee, Ph.D., first author, both at MD Anderson Cancer Center, along with colleagues, identified potential biomarkers in subgroups of high-grade serous ovarian cancer (HGSC). Biomarkers are unique biological indicators of an event, or the presence of a substance in the body. Biomarkers are useful … Continued
It’s hard to believe 2020 is almost over, and what a year it’s been. Despite the challenges wrought by the pandemic, we’re grateful to report that thanks to your support, OCRA grantees made great strides in ovarian cancer discoveries, bringing us ever closer to improving care and defeating this devastating disease: Revealed two cells of origin for high-grade serous ovarian cancer — … Continued
An international collaborative of scientists, including Dr. Ronald Chandler at Michigan State University, studied ARID1A mutations, which are specific gene mutations observed in deep ovarian and deep infiltrating endometriosis. The authors of the study noted that seeing a high frequency of these mutations in deep ovarian endometriosis supports evidence linking this to endometriosis-associated ovarian cancer. … Continued
In order to understand the complexities of how gene mutations affect an ovarian cancer diagnosis, OCRA-funded researcher Alexander Nikitin, MD, PhD and colleagues looked to see which ones drive, or possibly delay, the onset of the disease. “We found there were various genes that would help the process along, but interestingly, there were other genes … Continued
(July 27, 2020) Research from the Ovarian Cancer Association Consortium (OCAC) found that “using menopausal hormone therapy prior to diagnosis extends ovarian cancer survival.” This was found through a comprehensive analysis involving 6,419 post-menopausal women with ovarian carcinoma. Study authors concluded, “This large study is consistent with prior smaller studies, and further work is needed … Continued
(January 13, 2020) Thanks to your support, 22 top scientists at 19 eminent medical centers across the world will delve into important topics across the ovarian cancer landscape. In 2020, along with our other ongoing grants and programs, OCRA is investing nearly $9 million in the fight against ovarian cancer. These grants, awarded internationally for … Continued
(December 23, 2019) OCRA-funded scientist Dr. Sarah Gitto is making strides toward better harnessing the immune system to fight ovarian cancer. As reported recently in Gynecologic Oncology, Dr. Gitto and her colleagues at the University of Pennsylvania successfully created patient “avatars,” which mimic a patient’s biological profile based on a number of factors. Using these … Continued
OCRA-funded scientists have been hard at work this year, uncovering breakthroughs in ovarian cancer prevention, diagnostics, and treatment that can save women’s lives. Our grantees have made incredible progress toward better understanding and eradicating ovarian cancer. Their findings will have real-life impact for women and families battling this disease — and these stunning advancements would … Continued
(November 13, 2019) A study recently published in Nature Communications and led by OCRA grantee Dr. Rugang Zhang showed that the ARID1A protein plays a fundamental role in ensuring correct chromosome segregation when the cells divide. Specifically, ARID1A controls expression of another protein called STAG1 that is required to keep chromosome ends together. When ARID1A … Continued
In an effort to further understand disease initiation and progression, OCRA grantee Dr. Sumegha Mitra, along with colleagues at Indiana University, conducted research which revealed key changes in gene expression occurring during the initiation and early metastasis of ovarian cancer. Dr. Mitra and colleagues identified targets and pathways which can be explored in the future … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
